CERo Therapeutics Holdings, Inc.

Equities

CERO

US71902K1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:26:47 23/05/2024 BST			5-day change	1st Jan Change
0.988 ^USD	-0.20%		-9.73%	-90.73%

05-17	CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Phoenix Biotech Acquisition Corp. announced that it expects to receive $1.5 million in funding

December 15, 2022

Phoenix Biotech Acquisition Corp. announced a private placement of non-convertible promissory note for gross proceeds of $1,500,000 on December 16, 2022. The transaction includes participation from Phoenix Biotech Sponsor, LLC.

Latest news about CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-02	CI
Top Premarket Decliners	03-11	MT
Top Premarket Gainers	03-08	MT
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	03-07	CI
CERo Therapeutics Holdings, Inc. announced that it expects to receive $25 million in funding from Arena Business Solutions Global SPC II, Ltd.	02-22	CI
Top Premarket Decliners	02-20	MT
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	02-15	MT
Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer	02-15	CI
Phoenix Biotech Acquisition Corp. Announces Executive and Board Changes	02-15	CI
Phoenix Biotech Acquisition Corp. Appoints Charles Carter as Chief Financial Officer	02-15	CI
Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index	02-13	CI
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	02-13	CI
CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding	02-13	CI
Phoenix Biotech Acquisition Corp. Sinks 15% in Premarket Activity After Plunging 42% in Wednesday's Regular Trading	02-08	MT
Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC	02-04	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Phoenix Biotech Acquisition Corp. executed the letter of intent to acquire CERo Therapeutics, Inc. for $86.9 million.	04/06/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	24/03/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	24/03/23	CI
Phoenix Biotech Acquisition Corp. announced that it expects to receive $1.5 million in funding	15/12/22	CI
Phoenix Biotech Acquisition Corp. cancelled the acquisition of Intrinsic Medicine, Inc. from Phoenix Biotech Sponsor, LLC, Beryl Capital Management LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P. and others.	05/12/22	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI

Chart CERo Therapeutics Holdings, Inc.

Duration

Period

More charts

Company Profile

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Companyâs proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the bodyâs full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CERO THERAPEUTICS HOLDINGS, INC.	-90.73%	14.58M
VERTEX PHARMACEUTICALS INCORPORATED	+10.37%	115B
REGENERON PHARMACEUTICALS, INC.	+12.31%	106B
BIONTECH SE	-5.37%	24.69B
ARGENX SE	-1.22%	21.97B
GENMAB A/S	-4.78%	19.27B
BEIGENE, LTD.	-11.93%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.79%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.11%	12.13B

Bio Therapeutic Drugs